Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by ReachMD. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by ReachMD or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Nonsteroidal MRA & SGLT2i in People With CKD & T2D: Current Evidence and Rationale for Combination Therapy

 
Share
 

Manage episode 497289502 series 3128163
Content provided by ReachMD. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by ReachMD or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
CME credits: 0.25
Valid until: 06-06-2026
Claim your CME credit at https://reachmd.com/programs/cme/nonsteroidal-mra-sglt2i-in-people-with-ckd-t2d-current-evidence-and-rationale-for-combination-therapy/29909/
Can combining a nonsteroidal MRA and an SGLT2 inhibitor unlock new clinical potential for patients with type 2 diabetes and chronic kidney disease (CKD)? In this expert discussion, Dr. Jennifer Green and Dr. Hiddo Heerspink review the latest findings from the CONFIDENCE trial, which demonstrated a significant additive reduction in albuminuria—an important surrogate marker for kidney and cardiovascular risk—when finerenone and empagliflozin are used together. They explore the clinical rationale behind combination therapy, address persistent challenges in CKD detection, and consider the practical implications for implementing these therapies in high-risk populations.
  continue reading

386 episodes

Artwork
iconShare
 
Manage episode 497289502 series 3128163
Content provided by ReachMD. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by ReachMD or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
CME credits: 0.25
Valid until: 06-06-2026
Claim your CME credit at https://reachmd.com/programs/cme/nonsteroidal-mra-sglt2i-in-people-with-ckd-t2d-current-evidence-and-rationale-for-combination-therapy/29909/
Can combining a nonsteroidal MRA and an SGLT2 inhibitor unlock new clinical potential for patients with type 2 diabetes and chronic kidney disease (CKD)? In this expert discussion, Dr. Jennifer Green and Dr. Hiddo Heerspink review the latest findings from the CONFIDENCE trial, which demonstrated a significant additive reduction in albuminuria—an important surrogate marker for kidney and cardiovascular risk—when finerenone and empagliflozin are used together. They explore the clinical rationale behind combination therapy, address persistent challenges in CKD detection, and consider the practical implications for implementing these therapies in high-risk populations.
  continue reading

386 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play